06:08 PM EDT, 09/03/2025 (MT Newswires) -- Senseonics Holdings ( SENS ) said late Wednesday it has entered into a memorandum of understanding with Ascensia Diabetes Care to assume commercialization and distribution of Eversense 365 continuous glucose monitoring system.

Senseonics ( SENS ) said it would assume responsibility in the US from Jan. 1, 2026, and utilize Transition Service Agreements through Ascensia until fully established in markets outside the US.

Since 2020, Ascensia has held the exclusive worldwide distribution rights for Eversense products.

Senseonics ( SENS ) said bringing Eversense commercial sales and operations in-house should position the company to better meet payer, provider and patient needs.

The company reaffirmed its 2025 revenue guidance of $34 million to 38 million. It expects revenue improvement and gross margin expansion to 50% in 2026.

Shares were up about 18% in after-hours trading.